Instant immunity through chemically programmable vaccination and covalent self-assembly

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2009-03-17

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/pnas.0900147106PMID 19255430PMCID PMC2649956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.

  2009cited by this paper
• Antigen-specific human polyclonal antibodies from hyperimmunized cattle

  2009cited by this paper
• Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.

  2008cited by this paper
• Mechanisms for Decreased Function of B Cells in Aged Mice and Humans1

  2008cited by this paper
• Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

  2008cited by this paper
• Immunochemical termination of self-tolerance

  2008cited by this paper
• Alpha-v Integrins as Therapeutic Targets in Oncology

  2007cited by this paper
• Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.

  2007cited by this paper
• Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.

  2007cited by this paper
• Bifunctional ligands that target cells displaying the alpha v beta3 integrin.

  2007cited by this paper
• Bifunctional Ligands that Target Cells Displaying the αvβ3 Integrin

  2007cited by this paper
• Preparation of integrin α(v)β(3)-targeting Ab 38C2 constructs

  2007cited by this paper
• Breaking the one antibody-one target axiom.

  2006cited by this paper
• Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector

  2006cited by this paper
• Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.

  2004cited by this paper
• Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting.

  2004cited by this paper
• Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst

  2003cited by this paper
• Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors

  2002cited by this paper
• Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues.

  2001cited by this paper
• Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000influential reference
• The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

  1999cited by this paper
• Broadening the Aldolase Catalytic Antibody Repertoire by Combining Reactive Immunization and Transition State Theory: New Enantio- and Diastereoselectivities.

  1999cited by this paper
• Multiple event activation of a generic prodrug trigger by antibody catalysis.

  1999cited by this paper
• Alphav integrins mediate adhesion and migration of breast carcinoma cell lines.

  1998cited by this paper
• Catalytic Enantioselective Retro-Aldol Reactions: Kinetic Resolution of β-Hydroxyketones with Aldolase Antibodies.

  1998cited by this paper
• Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.

  1998cited by this paper
• Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.

  1998cited by this paper
• The Role of αv Integrins during Angiogenesis

  1998cited by this paper
• Clinical Significance of αvβ3 Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions

  1997cited by this paper
• Age‐related changes in antibody repertoire: contribution from T cells

  1997cited by this paper
• Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.

  1997cited by this paper
• Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma.

  1996cited by this paper
• Definition of Two Angiogenic Pathways by Distinct αv Integrins

  1995cited by this paper
• Definition of two angiogenic pathways by distinct alpha v integrins.

  1995cited by this paper
• Efficient Aldolase Catalytic Antibodies That Use the Enamine Mechanism of Natural Enzymes

  1995influential reference
• Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue.

  1995cited by this paper
• Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors.

  1992cited by this paper
• A receptor-mediated immune response using synthetic glycoconjugates

  1992cited by this paper
• Redirecting the immune response: ligand-mediated immunogenicity

  1991cited by this paper
• Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

  1990cited by this paper

• A Genetically Encoded Endogenous Antibody Recruitment Strategy for Innate Immune‐Mediated Killing of Cancer Cells

  2025cites this paper
• Proximity-inducing modalities: the past, present, and future.

  2023cites this paper
• The Chemistry of Creating Chemically Programmed Antibodies (cPAbs): Site-Specific Bioconjugation of Small Molecules.

  2023cites this paper
• Immuno-targeting of Gram-positive Pathogens via a Cell Wall Binding Tick Antifreeze Protein

  2022cites this paper
• Antibody‐Recruitment as a Therapeutic Strategy: A Brief History and Recent Advances

  2022cites this paper
• Sequential module coordination-driven programmable function switch of metal-molecule nanoframeworks for cancer theranostics

  2021cites this paper
• Induction of Endogenous Antibody Recruitment to the Surface of the Pathogen Enterococcus faecium.

  2020cites this paper
• Development and Characterization of Polymeric Peptides for Antibody Tagging of Bacterial Targets.

  2020cites this paper
• Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses†

  2020cites this paper
• Fc-Binding Antibody-Recruiting Molecules for Cancer Therapy: Exploiting Endogenous IgG Without antigen–Fab Interactions

  2019cites this paper
• RECRUITMENT OF ANTIBODESTO CANCER CELLS

  2017cites this paper
• Chapter Thirteen - Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics

  2017cites this paper
• PSMA-targeted bispecific Fab conjugates that engage T cells.

  2017cites this paper
• In vivo programming of endogenous antibodies via oral administration of adaptor ligands.

  2017cites this paper
• ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS

  2017cites this paper
• Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach

  2016cites this paper
• Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.

  2016cites this paper
• N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.

  2015cites this paper
• In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds

  2014cites this paper
• Chemically programmed antibodies.

  2014cites this paper
• Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti‐Carbohydrate Antibodies to Tumor Cells

  2014cites this paper
• Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

  2014cites this paper
• Effective molarity redux: Proximity as a guiding force in chemistry and biology.

  2013cites this paper
• Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

  2013cites this paper
• Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.

  2013cites this paper
• Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.

  2013cites this paper
• Selection and characterization of DNA aptamers

  2013cites this paper
• A Chemically Programmed Antibody Is a Long‐Lasting and Potent Inhibitor of Influenza Neuraminidase

  2012cites this paper
• Reprogramming urokinase into an antibody-recruiting anticancer agent.

  2012cites this paper
• Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

  2012cites this paper
• β-Diketone modified trastuzumab: a next-generation of Herceptin for resistant breast cancer cells?

  2012cites this paper
• Generation of Bispecific Antibodies by Chemical Conjugation

  2011cites this paper
• The Legumain Protease‐Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity

  2011cites this paper
• Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology

  2011cites this paper
• Supramolecular complexing of membane Siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM.

  2011cites this paper
• A chemically induced vaccine strategy for prostate cancer.

  2011cites this paper
• A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

  2010cites this paper
• A biosynthetic strategy for re-engineering the Staphylococcus aureus cell wall with non-native small molecules.

  2010cites this paper
• Chemically modified antibodies as diagnostic imaging agents.

  2010cites this paper
• Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

  2010cites this paper
• Grand challenge commentary: Synthetic immunology to engineer human immunity.

  2010cites this paper
• Targeted instant immunity

  2009cites this paper
• An efficient chemical approach to bispecific antibodies and antibodies of high valency.

  2009cites this paper
• An antibody-recruiting small molecule that targets HIV gp120.

  2009cites this paper
• Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.

  2009cites this paper
• Multiple catalytic aldolase antibodies suitable for chemical programming.

  2009cites this paper